Aditxt (NASDAQ:ADTX) Shares Down 8.1% – Time to Sell?

Aditxt, Inc. (NASDAQ:ADTX)’s stock price was down 8.1% during trading on Monday . The stock traded as low as $1.34 and last traded at $1.36. Approximately 140,549 shares traded hands during mid-day trading, a decline of 82% from the average daily volume of 791,783 shares. The stock had previously closed at $1.48.

Aditxt Stock Down 8.1%

The firm’s 50 day simple moving average is $2.57 and its 200 day simple moving average is $27.88.

Aditxt (NASDAQ:ADTX) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($8.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($26,400.00) by $26,391.88. The business had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.43 million.

Institutional Trading of Aditxt

A hedge fund recently raised its stake in Aditxt stock. IFP Advisors Inc raised its position in shares of Aditxt, Inc. (NASDAQ:ADTX) by 66,926.7% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,054 shares of the company’s stock after buying an additional 10,039 shares during the period. IFP Advisors Inc owned about 17.64% of Aditxt worth $45,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 15.54% of the company’s stock.

About Aditxt

Aditxt, Inc, a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues.